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Metastasis is a process consisting of cells spreading from the primary site of the cancer to distant parts of the body. Our
understanding of this spread is limited and molecular mechanisms causing particular characteristics of metastasis are still unknown.
There is some evidence that primary renal cell carcinoma (RCC) and metastases of RCC exhibit molecular differences that may effect
on the biological characteristics of the tumor. Some authors have detected differences in clear cell and nonclear cell component
between these 2 groups of tumors. Investigators have also determined that primary RCC and metastases of RCC diverge in their range
of renal-speciﬁc markers and other protein expression, gene expression pattern, and microRNA expression. There are also certain
proteins that are variously expressed in primary RCCs and their metastases and have effect on clinical outcome, e.g., endothelin
receptor type B, phos-S6, and CD44. However, further studies are needed on large cohorts of patients to identify differences
representing promising targets for prognostic purposes predicting disease-free survival and the metastatic burden of a patient as well
as their suitability as potential therapeutic targets. To sum up, in this review we have attempted to summarize studies connected with
differences between primary RCC and its metastases and their inﬂuence on the biological characteristics of renal cancer.r 2016 The
Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Kidney cancer is not a single disease because it
comprises a number of different cancers that occur in the
kidney, each with a different histology, which respond
differently to therapy and are caused by mutations in
different genes. Renal cell carcinoma (RCC) is the most
common kidney malignancy and the development of macro-
scopic metastases of RCC is the major cause of tumor-
associated deaths. The morbidity of RCC has consistently
increased by approximately 1.5% to 5.9% annually until
RCC is now the 10th most common in men and 14th most
common in women [1]. Pathologic stage, based on the size
of the tumor and the extent of invasion, grade, the
histological cell type as well as clinical parameters are.urolonc.2015.12.013
uthors. Published by Elsevier Inc. This is an open acc
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Despite this, none of these algorithms are 100% accurate.
Identiﬁcation of alterations that contribute to the variation in
tumor behavior and clinical outcome within organ-conﬁned
or metastatic RCC is needed for improved management of
RCC. Recent advances in understanding cancer as a genetic
disease have allowed the development of targeted molecular
therapies; however, resistance to these drugs remains a
signiﬁcant problem. Perhaps the key to understand the
different clinical outcome and resistance to treatment as
well as developing more effective treatments is an in depth
study of the metastatic tumors. Little is known about the
molecular mechanisms enabling metastatic spread of the
primary tumor; however, there is some evidence that
primary RCC and metastases of RCC exhibit molecular
differences. This article provides an overview of the most
important publications on genetic and molecular variations
between primary tumors and metastases of RCC.ess article under the CC BY-NC-ND license
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2.1. Histopathological analyses
The diagnosis of a metastasis of clear cell RCC (ccRCC)
is based almost entirely on the presence of classic morpho-
logic features along with a prior clinical history of ccRCC,
but sometimes it still can be challenging. This may be
owing to it presenting many years after the initial diagnosis
of a primary renal neoplasm or due to diverse histological
variations in RCC. Several immunohistochemistry panels
have proven useful in identifying primary or metastatic
RCC but some investigators showed variation in renal
marker expression in metastatic and primary tumors. Pan
et al. detected that metastatic lesions had signiﬁcantly
higher paired box gene (PAX2 and PAX8) H-scores than
matched primary tumors. In addition, they found complete
loss of marker expression in 6 metastases compared with
primary tumors, and this occurred signiﬁcantly more
frequently with RCC antigen [2]. Also, Barr et al. [3]
detected that intensity of PAX8 expression was higher in
metastases than in primary sites. PAX proteins are involved
in cell proliferation, apoptosis inhibitory, differentiation and
migration, and constitute, therefore, putative targets of
disruption during tumorigenesis. Besides, PAX2 expression
is promoted by the loss of von Hippel-Lindau (VHL) and
hypoxia in ccRCC. Lee et al. [4] performed immunohis-
tochemical staining for renal-speciﬁc markers, but it failed
to ﬁnd any signiﬁcant changes between these 2 groups of
tumors. In addition, they observed that 52.9% of metastatic
lesions contained a nonclear cell component such as
eosinophilic cytoplasm, rhabdoid features, and sarcomatoid
differentiation. Of the metastatic tumors, 24.4% lesions with
a nonclear cell component were composed of a nonclear cell
component alone without a typical clear cell area. In 81% of
metastatic lesions with a nonclear cell component, the
corresponding primary tumors showed the same
histologic type.
Sarcomatoid and rhabdoid components of ccRCC may
represent a subclone of the primary tumor that has under-
gone dedifferentiation. Molecular studies have shown con-
cordant loss of chromosome 3p and a VHL gene mutation in
rhabdoid and clear cells from the same case, suggesting
divergent differentiation from the same clone [5]. A few
authors have compared also vascularization in primary
RCCs and in metastatic RCC (mRCCs). Aziz et al. [6]
determined that the microvessel area, deﬁned as the total
area of microvessels in a given sample area, were higher in
primary tissues compared with their metastatic equivalents,
but Zhang et al. did not ﬁnd differences in the expression of
chitinase 3-like 1 and microvessel density, deﬁned as
measurable vessels in a sample area between primary and
metastatic sites [7]. Remark et al. analyzed the immune
environment of primary tumors and matched metastatic
lesions and found that each metastasis has different immune
inﬁltrates density that correlated with patient survival. Theyalso found a correlation between the density of inﬁltrating
DC-LAMPþ, CD8þ, and NKp46þ cells in the primary
tumor and in the corresponding lung metastasis. Similarity
of the immune pattern of the primary tumor and metastasis
could reﬂect, either a potential “imprinting” of the immune
microenvironment by the tumor cells or the possibility that
the immune contexture in the primary tumor, results in
“educated” immune cells that are recalled in the metastatic
sites [8].
2.2. Genomic and proteomic changes
Several authors have attempted to identify the genetic
changes underlying metastatic progression of human RCC.
Bissig et al. revealed that primary tumors and their
corresponding metastases were never identical. Genomic
changes that frequently occurred in metastases but not in the
corresponding primary tumors included 8p, 9p, 17qþ,
21qþ, and Xqþ [9]. The number of genetic aberrations
detected in metastases was higher than the number found in
primary ccRCC. This is consistent with the theory that RCC
progression from nonmetastatic primary tumors to meta-
stasis is driven by an accumulation of genetic changes. The
absence of shared genetic changes also includes the
possibility that a clonal relationship was missed because
of genetic heterogeneity within the primary tumor. Gerlin-
ger et al. [10] found differences in mutations in primary
tumors compared with metastatic tumors and provided
evidence of intratumor heterogeneity. A single tumor-
biopsy specimen reveals a minority of genetic aberrations
(including mutations, allelic imbalance, and ploidy) that are
present in an entire tumor. Cell clones with metastasis-
speciﬁc genetic changes may represent minor cell popula-
tions in the primary tumor. Besides, growth conditions may
differ at varying metastatic sites, giving growth advantage
to different cell clones in primary tumors and metastases.
Collating between ccRCC metastases and G1 primary
tumors identiﬁed 43 gene sets with signiﬁcant up-
regulation in metastases and 96 gene sets with signiﬁcant
down-regulation, respectively. When comparing ccRCC
metastases with G3 primary tumors, there were 20 gene
sets with signiﬁcant up-regulation in metastases and 149
gene sets with signiﬁcant down-regulation, respectively.
Pathways involved in intercellular adhesion, cell-matrix
adhesion, and apoptosis were signiﬁcantly down-regulated
in metastases and gene sets with signiﬁcant up-regulation in
metastases are involved in cell cycle control, energy
metabolism, and cellular migration. Metastatic cells reﬂect
increased resistance against signals that could induce
cellular death and these changes might contribute to a high
resistance against various cytotoxic therapies. Up-regulated
expression of genes that contribute to cellular motility in the
metastatic cells suggests that metastases have higher poten-
tial to migration than primary tumors [11]. Wuttig et al.
compared the expression proﬁles of a cohort of pulmonary
metastases of ccRCC with proﬁles of primary RCC and
Table 1
Differences in expression of miRNAs in metastases compared with primary RCC tumors
Study Up-regulated miRNAs Down-regulated miRNAs
White et al. [17, 21] miR-638, miR-1915, miR-149 MiR-10b, miR-196a, miR-27b
Wotschofsky et al. [18] miR-21, miR-155, miR-210, miR-223, miR-224, miR-296 miR-127, miR-370
Heinzelmann et al. [19] miR-199b-5p, miR-33b-3p and miR-34c-5p miR-204, miR-10b and miR-139-5p
Butz et al. [20] miR-30a-5p
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identiﬁed genes were the matrix metallopeptidases MMP7
and MMP9, chemokine receptor 3 (CXCR3), differentiation
marker membrane metallo-endopeptidase (CD10), apoptosis
inhibitor bcl2 and the cell-surface protein CD44. Most of
the genes that are dysregulated in metastases promote
metastasis-associated processes, like angiogenesis, cell
migration, cell motility, and cell adhesion [12]. Authors
also detected 167 genes that showed differential expression
in synchronously vs. metachronously metastasized tumors
[12]. Vaziri et al. sequenced the VHL tumor suppressor gene
that is associated with hereditary and sporadic forms of
ccRCC in paired tumor specimens and determined that in
40% of patients the VHL status differed between the
matched lesions. Also, sometimes, although the primary
tumor was wild-type, a mutant VHL gene was identiﬁed in
the metastatic lesion [13]. Abbas et al. [14] analyzed a set of
45 angiogenesis-associated genes and determined that most
genes showed similar expression proﬁles in primary tumors
and metastases.
Other authors have focused on microRNAs (miRNAs),
i.e., short non–protein-coding RNAs that silencing the
expression of genes involved in the control of cell develop-
ment, proliferation, and apoptosis [15]. miRNAs that have
prometastatic or antimetastatic effects have been calledTable 2
Differences in proteins expression in metastases compared with primary RCC tu
Symbol Name Function
MEK 1 Mitogen activated protein kinase-1 Proliferation
ALDH1 Aldehyde dehydrogenase enzyme Cellular differentiat
bcl2 Inhibiting apoptosis
14–3-3ζ 14–3-3 zeta/delta Cellular migration
Ki67 Proliferation marke
SNAIL Snail family zinc ﬁnger 1 Takes part in epithe
mesenchymal tra
SLUG Snail family zinc ﬁnger 2 Take part in epithe
mesenchymal tra
phos-AKT Phosphorylated v-akt murine thymoma
viral oncogene homolog 1
Promotes cell proli
4EBP1 4E-binding protein-1 Regulates cell grow
c-MYC v-myc avian myelocytomatosis viral
oncogene homolog
Promotes cell proli
Matriptase Transmembrane ser
cellular activator
factormetastamirs [16]. Investigators detected differences in
expression of miRNAs in metastases compared with pri-
mary tumors and found that miRNA expression was
dependent on the metastatic site, i.e., miR-199b showed
strongly increased expression in metastases from the lung
but was only weakly increased in distant metastases from
the brain. Wotschofsky et al. conﬁrmed the general down-
regulation of miRNAs in metastatic samples [17–19].
Table 1 summarizes ﬁndings noted by the cited authors.
White et al. evaluated molecular pathways and protein-
protein interactions to characterize mechanisms that drive
mRCC and identiﬁed 198 proteins that were dysregulated in
any of the mRCC samples. The top up-regulated proteins
were as follows: Ig lambda chain C regions (9IGLC1),
thymosin β4 (TMSB4X), and the ferritin light chain,
whereas the most down-regulated proteins were as follows:
agmatinase (AGMAT), aminobutyrate aminotransferase
(ABAT) and fatty acid-binding protein (FABP1). The most
common molecular functions identiﬁed included protein
binding, oxidoreductase ability, and nucleotide binding. The
authors also performed pathway analysis and detected that
the most signiﬁcant dysregulated pathways were glycolysis
or gluconeogenesis, pyruvate metabolism, and the citric
acid cycle. These data show that cancer cells reprogram
their metabolism and shift from aerobic to anaerobicmors
Authors Expression in metastases
compared to primary RCC
Aziz et al. [30] Higher
ion Abourbih et al. [31] Lower
Lee et al. [32] Higher
Masui et al. [33] Higher
r Laird et al. [34] Higher
lial to
nsition
Laird et al. [34] Higher
lial to
nsition
Laird et al. [34] Higher
feration Schultz et al. [35] Higher
th Schultz et al. [35] Higher
feration Schultz et al. [35] Higher
ine protease,
of growth
Mukai et al. [36] Higher
Table 3
Association between differences in expression of examined proteins in metastases compared with primary RCC and clinical outcomes (prognostic)
Symbol Name Function Study Expression in
metastases compared to
primary RCC
Clinical outcomes
CD31 [38] Platelet/endothelial cell
adhesion molecule
Adhesion molecule Wuttig et al. [12] Lower Longer TSS (P ¼ 0.096)
EDNRB Endothelin Receptor
type B
Member of the
Endothelin axis, take
part in tumor
progression
Wuttig et al. [12] Lower Longer TSS (P ¼ 0.006)
longer DFS (P ¼ 0.016)
TSPAN7 Tetraspanin 7 Expressed by
endothelial cells,
take part in tumor
progression
Wuttig et al. [12] Lower Longer TSS (P ¼ 0.012)
longer DFS (P ¼ 0.086)
phos-S6 Phosphorylated S6
protein
Regulates cell growth Schultz et al. [35] Higher Longer DSS (P ¼ 0.006)
Pfn1 Proﬁlin- 1 Cellular migration Masui et al. [33] Higher Shorter DFS
HNF-1β Hepatocyte nuclear
factor 1 beta
Transcription factor Buchner et al. [37] Lower Shorter TSS (P ¼ 0.04)
EZH2 Enhancer of zeste
homolog 2
Silenced genes that
regulate e.g. tumor
proliferation,
invasion, and
angiogenesis
Lee and Cho [28] No difference Shorter DFS (P ¼ 0.019)
shorter OS (P ¼ 0.066)
Xu et al. [29] Higher Shorter DSS (P ¼ 0.03)
PD-L1 [39] Programmed death
ligand 1
Promotes inactivation
and apoptosis of
activated anti-tumor
T cells
Jilaveanu et al. [24] Higher Not assessed
Thompson et al. [39] Not assessed Shorter DSS (P ¼ 0.002)
p53 Tumor protein p53 Induces apoptosis Zigeuner et al. [40] Higher Shorter DFS (P ¼ 0.01)
CD44 CD44 molecule Transmembrane
glycoproteins,
receptor for
hyaluronate
Lim et al. [41] Higher Shorter OS (P ¼ 0.011)
MET Receptor tyrosine
kinase
Growth factor
receptor
Mukai et al. [36] Higher Shorter OS (P ¼ 0.02)
VEGFR1 Vascular endothelial
growth factor
receptor 1
Growth factor receptor,
take part in
angiogenesis
Laird et al. [34] Higher Lower CSS (P ¼ 0.011)
VEGFD Vascular endothelial
growth factor ligand
D
Growth factor, take
part in angiogenesis
Laird et al. [34] No difference lower CSS (P ¼ 0.003)
CSS ¼ cancer-speciﬁc survival; DFS ¼ disease-free survival; DSS ¼ disease-speciﬁc survival; OS ¼ overall survival; TSS ¼ tumor-speciﬁc survival.
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arises in metastasis because of transient hypoxic episodes.
Cancer cells are also able to perform glycolysis and are
resistant to hypoxia, so will be selectively favored for
survival and growth [21]. Stickel et al. [22] determined that
metastases were similar to the primary tumors, both at the
level of HLA ligand presentation and mRNA but distant
metastases showed higher amounts of HLA class I mole-
cules compared to local lymph node metastases [23].
Jilaveanu et al. [24] detected that metastases demonstrated
higher expression of programmed death ligand 1 (PD-L1)
that connects with the costimulatory receptor on T cells and
promotes inactivation and apoptosis of activated anti-tumor
T cells [25] but in another study tumor cell PD-L1 levels
were not different in primary tumors and metastases [26].
Lee and Choe examined the expression of enhancer of zeste
homolog 2 (EZH2) that silenced genes that regulate, e.g.,tumor proliferation, invasion, and angiogenesis [27] and
showed that almost all metastases exhibited similar EZH2
expression as their primary tumors [28] but Xu et al.
determined that metastatic ccRCCs expressed the marker
more commonly than primary ccRCCs. In addition, tumors
in the liver and brain had the strongest EZH2 expression,
while lung metastases exhibited the lowest expression [29].
Table 2 shows differences in protein expression between
primary RCC and metastatic tumors.
2.3. Biomarkers
Differences in biology between primary tumors and
metastases give rise to searching a biomarker that predicts
aggressive clinical behavior of metastatic tumor. Buchner
et al. [37] identiﬁed that hepatocyte nuclear factor 1 beta
(HNF-1β), Na-dependent glucose transporter 1 (KIAA1919)
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groups with signiﬁcantly different prognoses. Other authors
also analyzed inﬂuence of expression of examined proteins
on clinical outcomes and detected that some of them have
prognostic value. Table 3 summarizes the ﬁndings noted by
the authors.3. Conclusion
The present review describes differences between pri-
mary renal tumors and their metastases at various levels of
cellular functionality associated with tumor biology and
clinical outcome. Disease progression in RCC is associated
with signiﬁcant changes in the expression of genes and
proteins, which probably makes metastatic cancer cells that
are more aggressive. These changes may partially explain
the difﬁculties connected with different clinical outcomes
within organ-conﬁned and metastatic RCC but at present,
no RCC biomarker is an appropriate candidate for use in
clinical practice. However, Wuttig et al. provided evidence
that “late metastases” diagnosed Z5 years after nephrec-
tomy and “early metastases” occurred r9 months after
nephrectomy showed differential expression of genes
involved in metastasis-associated processes and have
greater metastatic potential [12] despite clinical analyses
showing a better outcome of patients with a longer period
from nephrectomy to recurrence of the disease. This may
indicate that differential expression of genes and proteins in
a primary tumor and matched metastases is only one of the
causes of the various clinical behaviors of these tumors.
Greater analysis of the differences between primary tumors
and metastases, also on immunological level, is required to
gain a full assessment of the pathway changes, as these
differences may have implications for future work under-
standing the cancer biology. Further prospective studies on
large cohort patients are needed to identify differences
representing promising targets for prognostic purposes,
predicting the disease-free survival and metastatic burden
of a patient as well as their suitability as potential
therapeutic targets.References
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